Developer docs
API playgroundTry for free, no card

Search company profiles

Crinetics Pharmaceuticals

Full company profile

uuid0000itm

Namestring
Crinetics Pharmaceuticals
Legal namestring
Crinetics Pharmaceuticals, Inc.
Websiteurl
crinetics.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Crinetics Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and publicly traded on NASDAQ under ticker CRNX. The company develops and commercializes small molecule, selectively-targeted nonpeptide agonists and antagonists that address G-protein coupled receptors (GPCRs), with a strategic focus on rare endocrine diseases and endocrine-related tumors. Its core technology is a proprietary GPCR discovery engine that has produced 10+ disclosed pipeline programs targeting receptors including somatostatin receptor 2 (SST2), melanocortin receptor 2 (MC2R), TSH, PTH, SST3, GH, GLP-1, and GIP. The lead commercial product is PALSONIFY (paltusotine), the first and only once-daily oral SST2 agonist approved by the FDA (September 2025) and the European Commission (April 2026) for adults with acromegaly who had inadequate response to or are not candidates for surgery. Late-stage pipeline includes atumelnant (CRN04894), a first-in-class once-daily oral ACTH receptor antagonist in Phase 3 for classic congenital adrenal hyperplasia and Phase 1/2b for ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate in Phase 1/2 for SST2-expressing neuroendocrine tumors. The company has raised over $1.75 billion cumulatively, with $1.3 billion in cash and a stated runway into 2030.

Crinetics generates revenue primarily through product sales of PALSONIFY in the United States and, as of mid-2026, in the European Union, with additional de minimis collaboration and license revenue. Distribution operates through a specialty pharmacy model via partnerships with Orsini Healthcare (lead specialty pharmacy) and Biologics, supplemented by the company-operated CrinetiCARE patient support program and direct dispensing relationships with pituitary treatment centers. Pricing is not publicly disclosed. Q1 2026 total revenue was $10.7 million, including $10.3 million in PALSONIFY net product sales, representing sequential growth from $6.2 million in Q4 2025 and over 2,200% year-over-year growth off a small base. By end of Q1 2026, 263 unique healthcare providers had prescribed PALSONIFY, with approximately 70% of patients on reimbursed therapy. Geographic expansion is underway with Marketing Authorization Applications submitted in Brazil (March 2026) and Japan (April 2026 via partner SKK). The company is unprofitable, reporting a Q1 2026 net loss of $127.8 million and guiding to 2026 GAAP operating expenses of $600-650 million.

Short descriptiontext

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing oral, small molecule GPCR-targeted therapies for rare endocrine diseases. Its lead product PALSONIFY (paltusotine) is the first once-daily oral therapy approved for acromegaly, with a pipeline including atumelnant for CAH and CRN09682 for neuroendocrine tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare endocrine therapeutics, oral somatostatin agonists, GPCR small molecules, acromegaly treatment, specialty endocrinology pharmaceuticals
Industry1 code
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Endocrinology Specialty Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1PALSONIFY Product Sales
TypeOne Time License
Description

Crinetics generates revenue through commercial sales of PALSONIFY (paltusotine) in the United States and European Union for treatment of acromegaly. Q1 2026 net product revenue was $10.3 million, up from $5.4 million in Q4 2025. The company also received EU approval in April 2026 with planned launch in Germany and Austria, and has submitted applications in Brazil and Japan.

crinetics.com
2Collaboration and License Revenue
TypeLicensing Royalties
Description

The company generates minimal collaboration and license revenue, reported as $428,000 in Q1 2026 compared to $361,000 in Q1 2025.

crinetics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Crinetics Pharmaceuticals discovers, develops, and commercializes novel small molecule therapies for rare endocrine diseases and endocrine-related tumors. Its first commercial product, PALSONIFY (paltusotine), is an oral once-daily SST2 agonist approved in the US (September 2025) and EU (April 2026) for acromegaly. The pipeline includes atumelnant (oral ACTH antagonist for CAH and Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 93% of PATHFNDR-1 participants maintained stable IGF-1 levels (0.81x ULN at 96 weeks)
+6 more records
Product overview1 text field

Crinetics Pharmaceuticals is a global pharmaceutical company with its first commercial product PALSONIFY (paltusotine), an oral SST2 agonist approved for acromegaly. The company has a deep pipeline of 10+ disclosed programs including atumelnant (oral ACTH antagonist in Phase 3 for CAH and Phase 1/2b for Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors in Phase 1/2). Additional discovery programs target TSH, PTH, SST3, GH, GLP-1, and GIP receptors. The company also offers digital health tools including the Acromegaly Symptom Diary mobile app and patient support programs through CrinetiCARE.

Product and service5 records
1PALSONIFY (paltusotine)
CategoryCore commercial product
Description

A selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist; the first and only once-daily, oral therapy approved by FDA and EMA for the treatment of adults with acromegaly who had inadequate response to surgery and/or for whom surgery is not an option. Also in Phase 3 development for carcinoid syndrome associated with neuroendocrine tumors.

2Atumelnant (CRN04894)
CategoryPipeline product (late-stage)
Description

The first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. In development for classic congenital adrenal hyperplasia (Phase 3 CALM-CAH trial) and ACTH-dependent Cushing's syndrome (Phase 1/2b trial).

3CRN09682
CategoryPipeline product (early-stage)
Description

A nonpeptide drug conjugate candidate being developed to treat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and other SST2-expressing solid tumors. Currently in Phase 1/2 clinical trial.

4CrinetiCARE
CategoryPatient support program
Description

Patient support program for PALSONIFY, offering enrollment through specialty pharmacies (Orsini, Biologics) and direct dispenses from pituitary treatment centers. Includes free IGF-1 testing resources for patients.

5Acromegaly Symptom Diary Mobile App
CategoryDigital health tool
Description

A mobile application designed to help individuals with acromegaly track and notice potential breakthrough symptoms. Part of the Everyday Advocacy initiative to support patient self-advocacy in healthcare interactions.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Patient advocacy organization participating in Crinetics' Everyday Advocacy initiative steering committee. The initiative provides educational resources, support tools, and community connections for people living with acromegaly and other endocrine conditions.

2CARES Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Patient advocacy organization for congenital adrenal hyperplasia participating in the Everyday Advocacy steering committee. CARES Foundation provides expertise on patient needs for CAH management and advocacy.

crinetics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Patient advocacy organization participating in the Everyday Advocacy initiative steering committee, focusing on supporting people living with Cushing's syndrome and related conditions.

4Neuroendocrine Cancer Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Patient advocacy organization participating in the Everyday Advocacy steering committee, providing support and resources for patients with neuroendocrine cancers and related conditions.

crinetics.com
5Pituitary World News
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Patient advocacy organization participating in the Everyday Advocacy steering committee, focused on pituitary disease awareness and support for patients and caregivers.

crinetics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Crinetics entered into an exclusive license agreement with Ohio University in May 2026 to develop an early preclinical growth hormone receptor antagonist for the treatment of acromegaly. This partnership expands Crinetics' pipeline of endocrine therapies.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-26
Description

Orsini Healthcare was selected by Crinetics as the specialty pharmacy partner for PALSONIFY (paltusotine). PALSONIFY represents the first once-daily oral treatment approved for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The therapy is the fifth therapy to join Orsini's Endocrinology Center of Excellence, expanding patient access to this rare disease treatment.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recordati acquired Chiasma and markets Mycapssa, the other approved oral acromegaly therapy. Recordati is a direct competitor in the same patient population with a directly competing oral SST2-targeting product, making it the most directly comparable peer to Crinetics in the acromegaly franchise.

TypeDirect peer
Description

Ipsen markets Somatuline (lanreotide), a leading injectable somatostatin analog for acromegaly and neuroendocrine tumors. Ipsen is a direct incumbent competing for the same patient population that PALSONIFY targets with its oral, once-daily alternative.

TypeBroad incumbent
Description

Novartis markets Sandostatin (octreotide), the long-standing injectable somatostatin analog standard of care for acromegaly and NETs, and acquired AAA for Lutathera radioligand therapy. Novartis is a broad incumbent with overlapping capabilities but a much larger portfolio spanning many therapeutic areas.

TypeBroad incumbent
Description

Pfizer markets Somavert (pegvisomant), a growth hormone receptor antagonist used in acromegaly patients who fail first-line therapy. Pfizer is a broad incumbent offering a mechanistically distinct alternative for the same acromegaly population that Crinetics serves with PALSONIFY.

TypeDirect peer
Description

Neurocrine markets Crenessity (crinecerfont), an approved therapy for classic congenital adrenal hyperplasia, directly competing with Crinetics' atumelnant in the same CAH indication. Neurocrine is also broadly focused on endocrinology, making it one of the most directly comparable peers across Crinetics' pipeline.

TypeDirect peer
Description

Camurus markets octreotide depot formulations for acromegaly and neuroendocrine tumors, competing in the same SST2-targeting space as PALSONIFY and paltusotine. Camurus is a more focused direct peer as a specialty pharmaceutical company with deep somatostatin agonist expertise.

TypeEmerging player
Description

Ascendis Pharma is an endocrinology-focused rare disease company with TransCon hGH (Lonapegsomatropin) and other endocrine programs. While not directly competing in acromegaly or CAH, Ascendis is a peer in the broader rare endocrine specialty pharmaceutical space with similar commercial-stage dynamics.

TypeEmerging player
Description

Amryt Pharma, now part of Chiesi, had a presence in acromegaly and other rare endocrine disorders. It is an emerging player with overlapping rare endocrine focus but narrower portfolio compared to Crinetics' broader endocrine pipeline.

TypeEmerging player
Description

Theratechnologies markets Egrifta (tesamorelin) for HIV-associated lipodystrophy and has development programs in acromegaly. It is an emerging peer with partial overlap in the rare endocrine space served by Crinetics.

TypeEmerging player
Description

Soleno Therapeutics is focused on rare endocrine disorders including Prader-Willi syndrome, with an approved therapy in that space. While not a direct acromegaly competitor, Soleno is comparable as a small-cap commercial-stage rare endocrine pharmaceutical company.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Crinetics Pharmaceuticals

Endocrinology Specialty Pharmaceuticalscrinetics.com

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing oral, small molecule GPCR-targeted therapies for rare endocrine diseases. Its lead product PALSONIFY (paltusotine) is the first once-daily oral therapy approved for acromegaly, with a pipeline including atumelnant for CAH and CRN09682 for neuroendocrine tumors.

What Crinetics Pharmaceuticals does

Crinetics Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and publicly traded on NASDAQ under ticker CRNX. The company develops and commercializes small molecule, selectively-targeted nonpeptide agonists and antagonists that address G-protein coupled receptors (GPCRs), with a strategic focus on rare endocrine diseases and endocrine-related tumors. Its core technology is a proprietary GPCR discovery engine that has produced 10+ disclosed pipeline programs targeting receptors including somatostatin receptor 2 (SST2), melanocortin receptor 2 (MC2R), TSH, PTH, SST3, GH, GLP-1, and GIP. The lead commercial product is PALSONIFY (paltusotine), the first and only once-daily oral SST2 agonist approved by the FDA (September 2025) and the European Commission (April 2026) for adults with acromegaly who had inadequate response to or are not candidates for surgery. Late-stage pipeline includes atumelnant (CRN04894), a first-in-class once-daily oral ACTH receptor antagonist in Phase 3 for classic congenital adrenal hyperplasia and Phase 1/2b for ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate in Phase 1/2 for SST2-expressing neuroendocrine tumors. The company has raised over $1.75 billion cumulatively, with $1.3 billion in cash and a stated runway into 2030.

Crinetics generates revenue primarily through product sales of PALSONIFY in the United States and, as of mid-2026, in the European Union, with additional de minimis collaboration and license revenue. Distribution operates through a specialty pharmacy model via partnerships with Orsini Healthcare (lead specialty pharmacy) and Biologics, supplemented by the company-operated CrinetiCARE patient support program and direct dispensing relationships with pituitary treatment centers. Pricing is not publicly disclosed. Q1 2026 total revenue was $10.7 million, including $10.3 million in PALSONIFY net product sales, representing sequential growth from $6.2 million in Q4 2025 and over 2,200% year-over-year growth off a small base. By end of Q1 2026, 263 unique healthcare providers had prescribed PALSONIFY, with approximately 70% of patients on reimbursed therapy. Geographic expansion is underway with Marketing Authorization Applications submitted in Brazil (March 2026) and Japan (April 2026 via partner SKK). The company is unprofitable, reporting a Q1 2026 net loss of $127.8 million and guiding to 2026 GAAP operating expenses of $600-650 million.

Crinetics Pharmaceuticals firmographics

Firmographics
Name
Crinetics Pharmaceuticals
Legal name
Crinetics Pharmaceuticals, Inc.
Website
https://crinetics.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing oral, small molecule GPCR-targeted therapies for rare endocrine diseases. Its lead product PALSONIFY (paltusotine) is the first once-daily oral therapy approved for acromegaly, with a pipeline including atumelnant for CAH and CRN09682 for neuroendocrine tumors.
Ownership category
akta.pro rank

Crinetics Pharmaceuticals industry classification

Industry
Product category
Endocrinology Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Rare endocrine therapeutics
  • Oral somatostatin agonists
  • GPCR small molecules
  • Acromegaly treatment
  • Specialty endocrinology pharmaceuticals

Where Crinetics Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Crinetics Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. PALSONIFY Product Sales: Crinetics generates revenue through commercial sales of PALSONIFY (paltusotine) in the United States and European Union for treatment of acromegaly. Q1 2026 net product revenue was $10.3 million, up from $5.4 million in Q4 2025. The company also received EU approval in April 2026 with planned launch in Germany and Austria, and has submitted applications in Brazil and Japan.
  2. Collaboration and License Revenue: The company generates minimal collaboration and license revenue, reported as $428,000 in Q1 2026 compared to $361,000 in Q1 2025.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Crinetics Pharmaceuticals product offering

Product offering

Core offering

Crinetics Pharmaceuticals discovers, develops, and commercializes novel small molecule therapies for rare endocrine diseases and endocrine-related tumors. Its first commercial product, PALSONIFY (paltusotine), is an oral once-daily SST2 agonist approved in the US (September 2025) and EU (April 2026) for acromegaly. The pipeline includes atumelnant (oral ACTH antagonist for CAH and Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors).

Product overview

Crinetics Pharmaceuticals is a global pharmaceutical company with its first commercial product PALSONIFY (paltusotine), an oral SST2 agonist approved for acromegaly. The company has a deep pipeline of 10+ disclosed programs including atumelnant (oral ACTH antagonist in Phase 3 for CAH and Phase 1/2b for Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors in Phase 1/2). Additional discovery programs target TSH, PTH, SST3, GH, GLP-1, and GIP receptors. The company also offers digital health tools including the Acromegaly Symptom Diary mobile app and patient support programs through CrinetiCARE.

Differentiator

Problem solved

Functional benefit

Products and services

  • PALSONIFY (paltusotine) A selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist; the first and only once-daily, oral therapy approved by FDA and EMA for the treatment of adults with acromegaly who had inadequate response to surgery and/or for whom surgery is not an option. Also in Phase 3 development for carcinoid syndrome associated with neuroendocrine tumors.
  • Atumelnant (CRN04894) The first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. In development for classic congenital adrenal hyperplasia (Phase 3 CALM-CAH trial) and ACTH-dependent Cushing's syndrome (Phase 1/2b trial).
  • CRN09682 A nonpeptide drug conjugate candidate being developed to treat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and other SST2-expressing solid tumors. Currently in Phase 1/2 clinical trial.
  • CrinetiCARE Patient support program for PALSONIFY, offering enrollment through specialty pharmacies (Orsini, Biologics) and direct dispenses from pituitary treatment centers. Includes free IGF-1 testing resources for patients.
  • Acromegaly Symptom Diary Mobile App A mobile application designed to help individuals with acromegaly track and notice potential breakthrough symptoms. Part of the Everyday Advocacy initiative to support patient self-advocacy in healthcare interactions.

Quantifiable outcome

  • 93% of PATHFNDR-1 participants maintained stable IGF-1 levels (0.81x ULN at 96 weeks)
  • +6 more outcomes

Companies that use Crinetics Pharmaceuticals

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Crinetics Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Crinetics Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Acromegaly CommunitycoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in Crinetics' Everyday Advocacy initiative steering committee. The initiative provides educational resources, support tools, and community connections for people living with acromegaly and other endocrine conditions.
  • CARES FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization for congenital adrenal hyperplasia participating in the Everyday Advocacy steering committee. CARES Foundation provides expertise on patient needs for CAH management and advocacy.
  • Cushing's Support & Research FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy initiative steering committee, focusing on supporting people living with Cushing's syndrome and related conditions.
  • Neuroendocrine Cancer FoundationcoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy steering committee, providing support and resources for patients with neuroendocrine cancers and related conditions.
  • Pituitary World NewscoreStrategic or Co-development Partner · 2 June 2026Patient advocacy organization participating in the Everyday Advocacy steering committee, focused on pituitary disease awareness and support for patients and caregivers.
  • Ohio UniversityminorStrategic or Co-development Partner · 7 May 2026Crinetics entered into an exclusive license agreement with Ohio University in May 2026 to develop an early preclinical growth hormone receptor antagonist for the treatment of acromegaly. This partnership expands Crinetics' pipeline of endocrine therapies.
  • Orsini HealthcarecoreChannel Partner/ Reseller/ Distributor · 26 September 2025Orsini Healthcare was selected by Crinetics as the specialty pharmacy partner for PALSONIFY (paltusotine). PALSONIFY represents the first once-daily oral treatment approved for adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The therapy is the fifth therapy to join Orsini's Endocrinology Center of Excellence, expanding patient access to this rare disease treatment.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Crinetics Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Recordati: Recordati acquired Chiasma and markets Mycapssa, the other approved oral acromegaly therapy. Recordati is a direct competitor in the same patient population with a directly competing oral SST2-targeting product, making it the most directly comparable peer to Crinetics in the acromegaly franchise.
  • Ipsen: Ipsen markets Somatuline (lanreotide), a leading injectable somatostatin analog for acromegaly and neuroendocrine tumors. Ipsen is a direct incumbent competing for the same patient population that PALSONIFY targets with its oral, once-daily alternative.
  • Neurocrine Biosciences: Neurocrine markets Crenessity (crinecerfont), an approved therapy for classic congenital adrenal hyperplasia, directly competing with Crinetics' atumelnant in the same CAH indication. Neurocrine is also broadly focused on endocrinology, making it one of the most directly comparable peers across Crinetics' pipeline.
  • Camurus: Camurus markets octreotide depot formulations for acromegaly and neuroendocrine tumors, competing in the same SST2-targeting space as PALSONIFY and paltusotine. Camurus is a more focused direct peer as a specialty pharmaceutical company with deep somatostatin agonist expertise.

Broad incumbents

  • Novartis: Novartis markets Sandostatin (octreotide), the long-standing injectable somatostatin analog standard of care for acromegaly and NETs, and acquired AAA for Lutathera radioligand therapy. Novartis is a broad incumbent with overlapping capabilities but a much larger portfolio spanning many therapeutic areas.
  • Pfizer: Pfizer markets Somavert (pegvisomant), a growth hormone receptor antagonist used in acromegaly patients who fail first-line therapy. Pfizer is a broad incumbent offering a mechanistically distinct alternative for the same acromegaly population that Crinetics serves with PALSONIFY.

Emerging players

  • Ascendis Pharma: Ascendis Pharma is an endocrinology-focused rare disease company with TransCon hGH (Lonapegsomatropin) and other endocrine programs. While not directly competing in acromegaly or CAH, Ascendis is a peer in the broader rare endocrine specialty pharmaceutical space with similar commercial-stage dynamics.
  • Amryt Pharma (Chiesi Farmaceutici): Amryt Pharma, now part of Chiesi, had a presence in acromegaly and other rare endocrine disorders. It is an emerging player with overlapping rare endocrine focus but narrower portfolio compared to Crinetics' broader endocrine pipeline.
  • Theratechnologies: Theratechnologies markets Egrifta (tesamorelin) for HIV-associated lipodystrophy and has development programs in acromegaly. It is an emerging peer with partial overlap in the rare endocrine space served by Crinetics.
  • Soleno Therapeutics: Soleno Therapeutics is focused on rare endocrine disorders including Prader-Willi syndrome, with an approved therapy in that space. While not a direct acromegaly competitor, Soleno is comparable as a small-cap commercial-stage rare endocrine pharmaceutical company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Crinetics Pharmaceuticals social profiles

Digital presence

Crinetics Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Crinetics Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Crinetics Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Crinetics Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crinetics Pharmaceuticals

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals discovers, develops, and commercializes novel small molecule therapies for rare endocrine diseases and endocrine-related tumors. Its first commercial product, PALSONIFY (paltusotine), is an oral once-daily SST2 agonist approved in the US (September 2025) and EU (April 2026) for acromegaly. The pipeline includes atumelnant (oral ACTH antagonist for CAH and Cushing's syndrome) and CRN09682 (nonpeptide drug conjugate for neuroendocrine tumors).

Is Crinetics Pharmaceuticals a public or private company?

Crinetics Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Crinetics Pharmaceuticals founded?

Crinetics Pharmaceuticals was founded in 2008. It employs 501 to 1,000 people.

Where is Crinetics Pharmaceuticals based?

Crinetics Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Crinetics Pharmaceuticals make money?

Two revenue lines are on record. PALSONIFY Product Sales are the primary driver. The others are collaboration and License Revenue.

Who are Crinetics Pharmaceuticals's main competitors?

Direct peers on record are Recordati, Ipsen, Neurocrine Biosciences and Camurus. Broad incumbents are Novartis and Pfizer. Emerging players are Ascendis Pharma, Amryt Pharma (Chiesi Farmaceutici), Theratechnologies and Soleno Therapeutics.

Does Crinetics Pharmaceuticals have an API?

No public API is recorded for Crinetics Pharmaceuticals.

What industry is Crinetics Pharmaceuticals in?

Crinetics Pharmaceuticals's product category is Endocrinology Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrefisShould You Pick Vertex Stock Over Its Biotech Rivals?Vertex Pharmaceuticals trades at 34.1 times earnings, 69% more than Regeneron's 20.2, despite a 33.1% operating margin versus Regeneron's 30.4%. Vertex's revenue grew 10.5% over four quarters, slower than Regeneron's 18.6% and Alnylam's 56.2%. Management raised its fiscal 2026 revenue forecast to $13.15–13.25 billion, citing Crinetics acquisition.American City Business JournalsVertex cuts 78 jobs after $10B Crinetics acquisition closesVertex is laying off workers after closing its $10 billion purchase of Crinetics, as part of its integration plans at the San Diego biotech. The remainder of the article is reserved for subscribers.InvestegateResults analysis from Kepler Trust IntelligenceInternational Biotechnology Trust reported a 64.7% NAV per share gain for the 2026 financial year, outperforming the Nasdaq Biotechnology Index by 12.4 percentage points. The return was driven by 13 M&A deals, including Vertex's acquisition of Crinetics Pharmaceuticals. Managers expect M&A to remain elevated as large-cap pharma seeks to replace c. $400bn in patent-expiring revenues by 2033.The Motley FoolVertex (VRTX) Q3 2026 Earnings Call TranscriptVertex reported Q3 2026 revenue of $3.44 billion, up 12% year over year, and raised its full-year revenue guidance to $13.15-13.25 billion. The company's non-GAAP net income was $1.21 billion, and it completed the $9.0 billion net cash acquisition of Crinetics Pharmaceuticals.Seeking AlphaVertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics (NASDAQ:VRTX)Vertex Pharmaceuticals raised its 2026 revenue guidance to $13.15B-$13.25B, adding $40M-$50M from Crinetics. Q3 non-GAAP net income was $1.21B, with operating expenses revised to about $6B. The company plans to accelerate VX-017 in type 1 diabetes.FinancialContent Business PageVRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlookVertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, up 11.8% year-on-year, but adjusted EPS of $4.76 missed estimates by 0.5%. The company lifted its full-year revenue guidance to $13.2 billion and cited Crinetics integration and new product launches as key drivers. Management highlighted the upcoming launch of povetacicept in IgA nephropathy as a major milestone.Investing.comVertex Pharma meets Q3 estimates, raises revenue guidanceVertex Pharmaceuticals reported Q3 adjusted EPS of $4.76 and revenue of $3.44 billion, meeting estimates. The company raised its full-year 2026 revenue guidance to $13.15–13.25 billion, though the midpoint falls below analyst consensus. It also completed the Crinetics acquisition and expects a regulatory decision on povetacicept on November 30.MorningstarVertex Pharmaceuticals Raises Outlook Following Crinetics AcquisitionVertex Pharmaceuticals raised its outlook for sales and expenses to include growth from its Crinetics acquisition, expecting annual revenue of $13.15-13.25 billion. The higher outlook includes $40-50 million from Palsonify, and shares rose 5% to $579 after hours. Third-quarter profit fell to $653.6 million, or $2.56 per share.The Motley FoolVertex Spends Its CF Growth on New Launches: Rapid Earnings ReactionVertex Pharmaceuticals reported third-quarter revenue of $3.44 billion, up 12% year over year, with Alyftrek revenue reaching $706 million. Adjusted profit was flat as the company spent growth on new launches and the Crinetics deal. The FDA's Nov. 30 decision on povetacicept for IgA nephropathy is a key upcoming event.MarketWatchVertex Pharmaceuticals Raises Outlook Following Crinetics AcquisitionVertex Pharmaceuticals raised its sales and expense outlook to include growth from its Crinetics acquisition, expecting annual revenue of $13.15–13.25 billion. The company expects $40–50 million in revenue from Palsonify, and shares rose 5% to $579. Q3 profit fell to $653.6 million, with adjusted EPS of $4.76.